BioXcel Therapeutics
BTAI
40 hedge funds and large institutions have $7.28M invested in BioXcel Therapeutics in 2026 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 8 closing their positions.
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
28% more capital invested
Capital invested by funds: $5.66M → $7.28M (+$1.61M)
8.71% more ownership
Funds ownership: 16.17% → 24.88% (+8.7%)
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
2% less funds holding
Funds holding: 41 → 40 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$3.15M |
| 2 |
Millennium Management
New York
|
+$167K |
| 3 |
P
&Partners
Nashville,
Tennessee
|
+$133K |
| 4 |
Man Group
London,
United Kingdom
|
+$65.3K |
| 5 |
State Street
Boston,
Massachusetts
|
+$47.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$204K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$192K |
| 3 |
HF
HRT Financial
New York
|
-$28K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$27.3K |
| 5 |
EGM
Engineers Gate Manager
New York
|
-$19.7K |
BTAI Hedge Fund Activity: Q1 2026 in Review
40 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q1 2026, worth a combined $7.28M — up 28% from $5.66M a quarter earlier.
Fund positioning in BTAI was balanced in Q1 2026: 8 funds opened new positions, 8 closed out, 9 added to existing stakes and 7 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $3.15M. The largest seller was Jane Street, exiting entirely with an estimated $204K sold.
- 40 institutional investors held BioXcel Therapeutics (BTAI) as of Q1 2026, down from 41 in Q4 2025.
- Funds reported $7.28M of BioXcel Therapeutics stock for Q1 2026, up 28% quarter-over-quarter.
- 8 funds opened new BioXcel Therapeutics positions in Q1 2026 and 8 closed out, a net change of 0 holders.
- The largest BioXcel Therapeutics buyer in Q1 2026 was Armistice Capital, an estimated $3.15M added.
- The largest BioXcel Therapeutics seller in Q1 2026 was Jane Street, an estimated $204K sold.
Based on aggregated 13F filings for Q1 2026.